(AGIO) Agios Pharm - Overview

Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 1.678m USD | Total Return: -4.9% in 12m

Metabolic Medicines, Enzyme Activators, Rare Disease Therapies
Total Rating 23
Safety 25
Buy Signal -0.04
Biotechnology
Industry Rotation: -8.2
Market Cap: 1.68B
Avg Turnover: 21.6M
Risk 3d forecast
Volatility48.7%
VaR 5th Pctl7.59%
VaR vs Median-6.16%
Reward TTM
Sharpe Ratio0.34
Rel. Str. IBD18.8
Rel. Str. Peer Group17.8
Character TTM
Beta1.615
Beta Downside2.033
Hurst Exponent0.352
Drawdowns 3y
Max DD63.76%
CAGR/Max DD0.05
CAGR/Mean DD0.10
EPS (Earnings per Share) EPS (Earnings per Share) of AGIO over the last years for every Quarter: "2021-03": 26.95, "2021-06": -1.44, "2021-09": -1.56, "2021-12": -1.74, "2022-03": -1.74, "2022-06": -1.68, "2022-09": -1.49, "2022-12": 0.67, "2023-03": -1.47, "2023-06": -1.51, "2023-09": -1.64, "2023-12": -1.72, "2024-03": -1.45, "2024-06": -1.69, "2024-09": -1.47, "2024-12": -1.74, "2025-03": -1.55, "2025-06": -1.93, "2025-09": -1.78, "2025-12": -1.85, "2026-03": -1.69,
Last SUE: 0.03
Qual. Beats: 0
Revenue Revenue of AGIO over the last years for every Quarter: 2021-03: 41.409, 2021-06: 37.347, 2021-09: 0, 2021-12: 4.141E-5, 2022-03: 0.832, 2022-06: 5.582, 2022-09: 3.516, 2022-12: 4.31, 2023-03: 5.609, 2023-06: 6.712, 2023-09: 7.399, 2023-12: 7.103, 2024-03: 8.189, 2024-06: 8.615, 2024-09: 8.964, 2024-12: 10.73, 2025-03: 8.726, 2025-06: 12.455, 2025-09: 12.88, 2025-12: 19.967, 2026-03: 20.746,
Rev. CAGR: 44.25%
Rev. Trend: 98.1%
Last SUE: 2.40
Qual. Beats: 4

Warnings

Beneish M-Score -1.26 > -1.5 - likely earnings manipulation

Altman Z'' -9.00 < 1.0 - financial distress zone

Tailwinds

Confidence

Description: AGIO Agios Pharm

Agios Pharmaceuticals (AGIO) is a commercial-stage biopharmaceutical company focused on cellular metabolism and the development of therapies for rare hemolytic anemias. Its primary revenue driver is PYRUKYND (mitapivat), an enzyme activator currently approved for adults with pyruvate kinase (PK) deficiency and undergoing Phase 3 trials for sickle cell disease and thalassemia.

The company operates within the biotechnology sector, where business models typically require high research and development (R&D) expenditure to advance drug candidates through multi-phase clinical trials. Agios utilizes a targeted approach to genetic diseases, employing both small molecule activators and in-licensed siRNA technology to address metabolic disorders such as phenylketonuria and polycythemia vera.

The orphan drug market, in which Agios operates, often provides regulatory incentives such as extended market exclusivity and streamlined FDA review pathways for treatments targeting rare conditions. Analyzing the clinical trial milestones at ValueRay can offer deeper insights into the companys long-term valuation. Headquartered in Cambridge, Massachusetts, the firm maintains a pipeline focused on expanding the indications for its PK activator platform.

Headlines to Watch Out For
  • PYRUKYND commercial adoption in adult pyruvate kinase deficiency drives core revenue growth
  • Phase 3 clinical trial results for mitapivat in thalassemia and sickle cell
  • Regulatory approval timelines for pediatric PK deficiency and thalassemias expand market
  • Royalty revenue from Servier oncology assets provides non-dilutive balance sheet support
  • R&D spending and cash burn rate for pipeline candidates impact valuation
Piotroski VR-10 (Strict) 1.0
Net Income: -422.6m TTM > 0 and > 6% of Revenue
FCF/TA: -0.32 > 0.02 and ΔFCF/TA -6.51 > 1.0
NWC/Revenue: 1.17k% < 20% (prev 2.47k%; Δ -1.30k% < -1%)
CFO/TA -0.32 > 3% & CFO -380.4m > Net Income -422.6m
Net Debt/EBITDA: error (EBITDA <= 0)
Current Ratio: 14.19 > 1.5 & < 3
Outstanding Shares: last quarter (58.8m) vs 12m ago 2.30% < -2%
Gross Margin: 82.07% > 18% (prev 0.80%; Δ 8.13k% > 0.5%)
Asset Turnover: 4.82% > 50% (prev 2.38%; Δ 2.44% > 0%)
Interest Coverage Ratio: error (cannot be calculated; needs correct EBITDA TTM and Interest Expense TTM)
Altman Z'' -9.00
A: 0.65 (Total Current Assets 834.8m - Total Current Liabilities 58.8m) / Total Assets 1.18b
B: -0.56 (Retained Earnings -660.8m / Total Assets 1.18b)
C: -0.35 (EBIT TTM -475.5m / Avg Total Assets 1.37b)
D: -8.71 (Book Value of Equity -661.1m / Total Liabilities 75.9m)
Altman-Z'' = -9.00 = D
Beneish M -1.26
DSRI: 2.71 (Receivables 16.1m/3.34m, Revenue 66.0m/37.0m)
GMI: 0.97 (GM 82.07% / 79.77%)
AQI: 0.77 (AQ_t 0.26 / AQ_t-1 0.34)
SGI: 1.78 (Revenue 66.0m / 37.0m)
TATA: -0.04 (NI -422.6m - CFO -380.4m) / TA 1.18b)
Beneish M = -1.26 (Cap -4..+1) = D
What is the price of AGIO shares?

As of May 24, 2026, the stock is trading at USD 28.14 with a total of 751,629 shares traded.
Over the past week, the price has changed by -0.11%, over one month by +5.31%, over three months by -6.82% and over the past year by -4.90%.

Is AGIO a buy, sell or hold?

Agios Pharm has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy AGIO.

  • StrongBuy: 3
  • Buy: 3
  • Hold: 3
  • Sell: 0
  • StrongSell: 0

What are the forecasts/targets for the AGIO price?
Analysts Target Price 41.1 46.2%
Agios Pharm (AGIO) - Fundamental Data Overview as of 20 May 2026
P/E Forward = 2.4655
P/S = 25.4011
P/B = 0.6799
Revenue TTM = 66.0m USD
EBIT TTM = -475.5m USD
EBITDA TTM = -470.3m USD
Long Term Debt = 16.9m USD (estimated: total debt 35.7m - short term 18.8m)
Short Term Debt = 18.8m USD (from shortTermDebt, last quarter)
Debt = 35.7m USD (from shortLongTermDebtTotal, last quarter) (leases 35.7m already included)
Net Debt = -701.3m USD (calculated: Debt 35.7m - CCE 737.0m)
Enterprise Value = 976.4m USD (1.68b + Debt 35.7m - CCE 737.0m)
 Interest Coverage Ratio = unknown (Ebit TTM -475.5m / Interest Expense TTM 0.0)
 EV/FCF = -2.54x (Enterprise Value 976.4m / FCF TTM -384.7m)
FCF Yield = -39.40% (FCF TTM -384.7m / Enterprise Value 976.4m)
 FCF Margin = -582.5% (FCF TTM -384.7m / Revenue TTM 66.0m)
 Net Margin = -639.8% (Net Income TTM -422.6m / Revenue TTM 66.0m)
 Gross Margin = 82.07% ((Revenue TTM 66.0m - Cost of Revenue TTM 11.8m) / Revenue TTM)
Gross Margin QoQ = 87.07% (prev 84.25%)
Tobins Q-Ratio = 0.82 (Enterprise Value 976.4m / Total Assets 1.18b)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt 35.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -375.7m (EBIT -475.5m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 14.19 (Total Current Assets 834.8m / Total Current Liabilities 58.8m)
Debt / Equity = 0.03 (Debt 35.7m / totalStockholderEquity, last quarter 1.11b)
 Debt / EBITDA = 1.49 (negative EBITDA) (Net Debt -701.3m / EBITDA -470.3m)
 Debt / FCF = 1.82 (negative FCF - burning cash) (Net Debt -701.3m / FCF TTM -384.7m)
 Total Stockholder Equity = 1.24b (last 4 quarters mean from totalStockholderEquity)
RoA = -30.84% (Net Income -422.6m / Total Assets 1.18b)
RoE = -22.24% (Net Income TTM -422.6m / Total Stockholder Equity 1.90b)
RoCE = -24.81% (EBIT -475.5m / Capital Employed (Equity 1.90b + L.T.Debt 16.9m))
 RoIC = -36.07% (negative operating profit) (NOPAT -375.7m / Invested Capital 1.04b)
 WACC = 11.42% (E(1.68b)/V(1.71b) * Re(11.66%) + D(35.7m)/V(1.71b) * Rd(0.0%) * (1-Tc(0.21)))
Discount Rate = 11.66% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 77.78 | Cagr: 2.26%
 [DCF] Fair Price = unknown (Cash Flow -384.7m)
 EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.03 | # QB: 0
Revenue Correlation: 98.15 | Revenue CAGR: 44.25% | SUE: 2.40 | # QB: 4
EPS current Quarter (2026-06-30): EPS=-1.58 | Chg30d=+6.49% | Revisions=-14% | Analysts=7
EPS next Quarter (2026-09-30): EPS=-1.46 | Chg30d=+8.40% | Revisions=+20% | Analysts=9
EPS current Year (2026-12-31): EPS=-5.97 | Chg30d=+8.29% | Revisions=+50% | GrowthEPS=+16.2% | GrowthRev=+130.8%
EPS next Year (2027-12-31): EPS=-4.68 | Chg30d=+9.00% | Revisions=+20% | GrowthEPS=+23.0% | GrowthRev=+108.4%
[Analyst] Revisions Ratio: +50%